Exact Mass: 491.1791
Exact Mass Matches: 491.1791
Found 158 metabolites which its exact mass value is equals to given mass value 491.1791
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Asn Glu Thr Glu
Thr Gln Glu Asp
Thr Glu Gln Asp
Cys Asn Gln Gln
Cys Pro Ser Trp
Cys Pro Trp Ser
Cys Gln Asn Gln
Cys Gln Gln Asn
Cys Ser Pro Trp
Cys Ser Trp Pro
Cys Trp Pro Ser
Cys Trp Ser Pro
Asp Asp Asp Lys
Asp Asp Lys Asp
Asp Glu Gln Thr
Asp Glu Thr Gln
Asp Lys Asp Asp
Asp Gln Glu Thr
Asp Gln Thr Glu
Asp Thr Glu Gln
Asp Thr Gln Glu
Glu Asp Gln Thr
Glu Asp Thr Gln
Glu Glu Asn Thr
Glu Glu Gln Ser
Glu Glu Ser Gln
Glu Glu Thr Asn
Glu Asn Glu Thr
Glu Asn Thr Glu
Glu Gln Asp Thr
Glu Gln Glu Ser
Glu Gln Ser Glu
Glu Gln Thr Asp
Glu Ser Glu Gln
Glu Ser Gln Glu
Glu Thr Asp Gln
Glu Thr Glu Asn
Glu Thr Asn Glu
Glu Thr Gln Asp
Lys Asp Asp Asp
Met Met Asn Pro
Met Met Pro Asn
Met Asn Met Pro
Met Asn Asn Asn
Met Asn Pro Met
Met Pro Met Asn
Met Pro Asn Met
Asn Cys Gln Gln
Asn Glu Glu Thr
Asn Met Met Pro
Asn Met Asn Asn
Asn Met Pro Met
Asn Asn Met Asn
Asn Asn Asn Met
Asn Pro Met Met
Asn Gln Cys Gln
Asn Gln Gln Cys
Asn Thr Glu Glu
Pro Cys Ser Trp
Pro Cys Trp Ser
Pro Met Met Asn
Pro Met Asn Met
Pro Asn Met Met
Pro Ser Cys Trp
Pro Ser Trp Cys
Pro Trp Cys Ser
Pro Trp Ser Cys
Gln Cys Asn Gln
Gln Cys Gln Asn
Gln Asp Glu Thr
Gln Asp Thr Glu
Gln Glu Asp Thr
Gln Glu Glu Ser
Gln Glu Ser Glu
Gln Glu Thr Asp
Gln Asn Cys Gln
Gln Asn Gln Cys
Gln Gln Cys Asn
Gln Gln Asn Cys
Gln Ser Glu Glu
Gln Thr Asp Glu
Gln Thr Glu Asp
Ser Cys Pro Trp
Ser Cys Trp Pro
Ser Glu Glu Gln
Ser Glu Gln Glu
Ser Pro Cys Trp
Ser Pro Trp Cys
Ser Gln Glu Glu
Ser Trp Cys Pro
Ser Trp Pro Cys
Thr Asp Glu Gln
Thr Asp Gln Glu
Thr Glu Asp Gln
Thr Glu Glu Asn
Thr Glu Asn Glu
Thr Asn Glu Glu
Thr Gln Asp Glu
Trp Cys Pro Ser
Trp Cys Ser Pro
Trp Pro Cys Ser
Trp Pro Ser Cys
Trp Ser Cys Pro
Trp Ser Pro Cys
Vestipitant
D018377 - Neurotransmitter Agents > D064729 - Neurokinin-1 Receptor Antagonists C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent
Flunixin Meglumine
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents D058633 - Antipyretics
4-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-N-[4-(4-morpholinylsulfonyl)phenyl]benzamide
N-[2-(3-methoxyphenyl)-4-[(4-methoxyphenyl)methoxy]-6-quinolinyl]-3-pyridinecarboxamide
4-Morpholinyl-[4-[3-[4-(4-morpholinylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl]-1-piperidinyl]methanone
6-(Methylamino)hexane-1,2,3,4,5-pentol 2-[2-methyl-3-(trifluoromethyl)anilino]-3-pyridinecarboxylic acid
N-[(1R,3S,4aR,9aS)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
2-fluoro-N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzenesulfonamide
2-fluoro-N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzenesulfonamide
2-fluoro-N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzenesulfonamide
2-fluoro-N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzenesulfonamide
4-fluoro-N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-3-oxanyl]benzenesulfonamide
4-fluoro-N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-3-oxanyl]benzenesulfonamide
4-fluoro-N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-3-oxanyl]benzenesulfonamide
N-[(1R,3R,4aR,9aS)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
N-[(1S,3R,4aS,9aR)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
N-[(1S,3S,4aR,9aS)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
4-fluoro-N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzenesulfonamide
2-fluoro-N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzenesulfonamide
2-fluoro-N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzenesulfonamide
2-fluoro-N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzenesulfonamide
2-fluoro-N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzenesulfonamide
4-fluoro-N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-3-oxanyl]benzenesulfonamide
4-fluoro-N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-3-oxanyl]benzenesulfonamide
4-fluoro-N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-3-oxanyl]benzenesulfonamide
4-fluoro-N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-3-oxanyl]benzenesulfonamide
4-fluoro-N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-3-oxanyl]benzenesulfonamide
N-[(1S,3S,4aS,9aR)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
N-[(1R,3R,4aS,9aR)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
N-[(1R,3S,4aS,9aR)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
N-[(1S,3R,4aR,9aS)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-pyridinecarboxamide
4-[4-[(1S,5R)-3-(3-methoxyphenyl)sulfonyl-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]-N,N-dimethylbenzamide
FSI-TN42
ALDH1A1/2-IN-1 is an ALDH1A1 and ALDH1A2 inhibitor that can be used for preventing spermatogenesis[1].